Mainz Biomed N.V. reported its financial results for 2024, with total revenue of $893,991 for the trailing twelve months (TTM) as of September 23, 2025. While revenue from its lab partner network increased by 33% year-over-year, overall revenue decreased by 0.17% in 2024 compared to 2023.
The company reported a TTM gross profit of $574,883, resulting in a gross profit margin of 64.31%. However, significant operating expenses led to a TTM operating profit margin of -2091.23% and a net profit margin of -2421.80%, with a TTM net income of -$21.65 million.
Mainz Biomed's operating loss decreased by 30% and net loss by 18% in 2024, reflecting cost-cutting efforts and a sharper strategic focus. TTM operating cash flow was -$17.09 million and free cash flow was -$17.34 million, indicating continued investment in R&D and early commercialization phases.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.